Clinical Trial

Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase 1/2 study will evaluate the safety, reactogenicity and immunogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Parts 1 and 2) or Placebo (Part 3).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-14; most recent amendment 2026-05-18.
Status change: Recruiting → Active, Not Recruiting 2026-05-07
Status change: Not Yet Recruiting → Recruiting 2025-08-05
Trial Details
NCT Number NCT06984094
Lead Sponsor Clover Biopharmaceuticals AUS Pty
Conditions RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection
Enrollment 612 participants
Start Date 2025-06-18
Primary Completion 2028-03 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-20